首页|七味白术散加味治疗肝硬化腹泻临床观察

七味白术散加味治疗肝硬化腹泻临床观察

扫码查看
目的:观察七味白术散加味治疗肝硬化腹泻的临床疗效。方法:选取确诊的96例肝硬化腹泻患者,随机分为两组各48例。两组均予肝硬化西医常规治疗,对照组在此基础上予双歧杆菌四联活菌口服,治疗组予七味白术散加味治疗,疗程均为2周,比较两组临床疗效以及肠道sIgA水平变化、肠道菌群的改善情况。结果:治疗组总有效率为95。83%,对照组总有效率81。25%,两组比较差异有统计学意义(P<0。05);治疗后,治疗组患者的ALT、AST、TBIL改善程度明显优于对照组(P<0。05);治疗组肠道sIgA水平、肠道菌群改善水平均明显优于对照组(P<0。05)。结论:七味白术散加味治疗肝硬化腹泻疗效较好,可改善患者肝功能水平及肠道有益菌群生长,增加患者肠道sIgA水平。
Efficacy observation of modified Qiwei Baizhu powder on hepatocirrhosis-caused diarrhea
Objective:To observe the clinical efficacy of modified Qiwei Baizhu powder on hepatocirrhosis-caused diarrhea.Methods:96 cases of patients with hepatocirrhosis-caused diarrhea were selected and randomly divided into two group,48 cases in each group.Both groups were treated with conventional western medicine for hepatocirrhosis.On the basis of aboved treatment,the control group was treated plus with oral bifidobacterium tetravaccine tablets(live),while the treatment group was treated plus with modified Qiwei Baizhu powder,and the course of treatment was 2 weeks.Clinical efficacy,change of intestinal sIgA level and improvement of intestinal flora were compared bwtween two groups.Results:The total effective rate of treatment group was 95.83%,that of control group was 81.25%,and the comparative difference between two groups was statistically significant(P<0.05).After treatment,the improvement of ALT,AST and TBIL of patients in the treatment group was significantly better than that in the control group(P<0.05);the level of intestinal sIgA and the improvement of intestinal flora of treatment group were significantly better than those of control group(P<0.05).Conclusion:The clinical efficacy of modified Qiwei Baizhu powder on hepatocirrhosis-caused diarrhea is better,which can improve the level of liver function of patients and the growth of beneficial intestinal flora,and increase the level of intestinal sIgA of patients.

hepatocirrhosisdiarrheaQiwei Baizhu powdertherapy of TCM

任燕怡、李霞、冯培民、何俊余、马悦

展开 >

成都中医药大学附属医院(成都610032)

四川大学校医院

肝硬化 腹泻 七味白术散 中医药疗法

四川省中医药局科学技术研究专项

2023MS230

2024

山西中医
山西省中医药学会 山西中医药研究院

山西中医

影响因子:0.59
ISSN:1000-7156
年,卷(期):2024.40(4)
  • 10